Cumberland Pharmaceuticals (CPIX) Earning Somewhat Positive Media Coverage, Report Finds

News stories about Cumberland Pharmaceuticals (NASDAQ:CPIX) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cumberland Pharmaceuticals earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.3472842725256 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

CPIX traded up $0.02 during trading hours on Monday, hitting $6.61. The stock had a trading volume of 401 shares, compared to its average volume of 16,388. Cumberland Pharmaceuticals has a 1 year low of $5.39 and a 1 year high of $7.96. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.50.

How to Become a New Pot Stock Millionaire

TRADEMARK VIOLATION NOTICE: “Cumberland Pharmaceuticals (CPIX) Earning Somewhat Positive Media Coverage, Report Finds” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/09/cumberland-pharmaceuticals-cpix-earning-somewhat-positive-media-coverage-report-finds.html.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. It marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H.

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply